S

Spectrum Pharmaceuticals Inc
F:NTR

Watchlist Manager
Spectrum Pharmaceuticals Inc
F:NTR
Watchlist
Price: 0.925 EUR Market Closed
Market Cap: €189.9m

Net Margin

-296.9%
Current
Improving
by 239.1%
vs 3-y average of -535.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-296.9%
=
Net Income
$-65m
/
Revenue
$25.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-296.9%
=
Net Income
€-65m
/
Revenue
$25.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Spectrum Pharmaceuticals Inc
F:NTR
189.9m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 15 072 companies
10th percentile
-296.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Spectrum Pharmaceuticals Inc
Glance View

Market Cap
189.9m EUR
Industry
Biotechnology

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.

NTR Intrinsic Value
Not Available
S
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-296.9%
=
Net Income
$-65m
/
Revenue
$25.7m
What is Spectrum Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Spectrum Pharmaceuticals Inc is -296.9%, which is above its 3-year median of -535.9%.

How has Net Margin changed over time?

Over the last 4 months, Spectrum Pharmaceuticals Inc’s Net Margin has increased from -798.1% to -296.9%. During this period, it reached a low of -798.1% on Dec 31, 2022 and a high of -273.8% on May 1, 2023.

Back to Top